Kornimate/medical-research-clean huggingface dataset:
evaluation of transcranial doppler vasoconstrictor vasoreactivity during general anesthesia in hypertensive patients

Conditions: Hypertensive Disease; Elderly; Vasopressors; General Anesthesia

Summary: during a general anesthesia, people over 65 years old and hypertensive, have a modification of the vasoreactivity and their cerebral blood flow under vasoconstrictor such as norepinephrine or phenylephrine. we study the variation of the average velocity of the average cerebral artery under vasoconstrictor and during a modification of end tidal co2 (etco2) by transcranial doppler.

general anesthesia induces a sympathetic block frequently leading to hypotension, especially in elderly and hypertensive patients. currently, phenylephrine (pe) and norepinephrine (ne) are commonly used in clinical practice to address this arterial pressure drop. their cardiovascular effects are not exactly the same, even though they both increase mean blood pressure. maintenance of mean arterial pressure is not the only hemodynamic goal during general anesthesia in the elderly. cognitive disorders have been demonstrated during post-anesthetic awakening. cerebral hemodynamics is assessed by analyzing the speed of blood flow in the middle cerebral artery using transcranial doppler (dtc). it measures the systolic and diastolic speed as well as the pulsatility index, which are predictive factors for lowering cerebral blood flow.

Eligibility criteria:
inclusion criteria: * older over 65 years * high blood pressure disease * need general anesthesia * need vasopressors : norepinephrine or phenylephrine * temporal window of transcranial doppler is viable exclusion criteria: * acute, valvular, rhythmic or ischemic cardiovascular pathology * severe arthritis (stage 3) * intra-cranial pathology * significant carotid stenosis (\> 40%) or carotid endarterectomy * cervical surgery * taking a premedication that can modify cerebral vasoreactivity * insulin-dependent diabetes for more than 10 years * person under judicial protection * opposition to data processing

Keywords: cerebral vasoreactivity transcranial doppler hypertensive disease elderly vasopressors general anesthesia
implementing an effective diabetes intervention among low-income immigrants

Conditions: Type 2 Diabetes

Summary: the goal of this ideal project is to examine the effectiveness and implementation process of the video-based diabetes self-management education and support (dsmes) + community health worker (chw) (hereafter: "ideal") intervention compared with a wait-list control group (hereafter: "control") to improve glycemic control among chinese immigrants with type 2 diabetes (t2d) in new york city (nyc). participants will be randomized with equal allocation to one of the 2 groups. the ideal group will receive 1 dsmes brief video/week for 24 weeks delivered via text message. the chw will assess participants' sdoh barriers to t2d care and link them to available resources in the community. the control group will continue to receive their usual care and at the end of the study, they will receive dsmes videos.


Eligibility criteria:
inclusion criteria: participants must: 1. self-identify as a chinese immigrant; 2. be between 18-70 years old, 3. have a diagnosis of t2d in the medical record; 4. have had an appointment with a physician for routine t2d care within the past 12 months; 5. have a most recent hba1c \> or = 8%; 6. be willing to receive brief videos regarding t2d management, and 7. possess a smartphone or, if they do not have one, be willing and able to use a study smartphone. exclusion criteria: 1. unable or unwilling to provide informed consent; 2. unable to participate meaningfully in the intervention (e.g., uncorrected sight and hearing impairment); 3. unwilling to accept randomization assignment; 4. is pregnant, plans to become pregnant in the next 6 months, or becomes pregnant during the study, or 5. is breastfeeding (e.g., they may have potential dietary restrictions).

Keywords: mobile health mhealth
the efficacy of spsipb on postoperative pain and analgesic consumption in patients undergoing vats

Conditions: Post Operative Pain

Summary: the aim of this study is to investigate the postoperative analgesic efficacy of spsipb and its effect on opioid consumption in patients undergoing video-assisted thoracoscopic surgery (vats).

there were two randomized groups: group s (spsipb) (n=12), group c (no block) (n=12). all patients had standard general anesthesia. group s had serratus posterior superior intercostal plane block (spsipb) with 0.25% bupivacaine (total volume of 30 ml) at the end of the surgery. group control had only tramadol for postoperative pain. numerical rating scale (nrs) was used to assess postoperative pain on 1st, 6th, 12th and 24th hour after the surgery. total tramadol consumption was calculated using patient-controlled analgesia (pca) device.

Eligibility criteria:
inclusion criteria: * adult patients older than 18 years of age who underwent video-assisted thoracoscopic surgery (vats) under general anesthesia and were american society of anesthesiologists (asa) i-ii-iii according to the asa risk classification. exclusion criteria: * patients who did not give consent, * patients with coagulopathy, * patients with signs of infection at the block application site, * patients using anticoagulants, * patients with local anesthetic drug allergies, * patients undergoing open surgery, * patients with unstable hemodynamics, * patients who could not cooperate during postoperative pain assessment

Keywords: serratus posterior superior intercostal plane block video assisted thoracoscopic surgery postoperative pain regional anesthesia
comparison of autogenic and allogenic nk immunotherapy on the outcome of recurrent solid tumors

Conditions: Malignant Solid Tumour

Summary: the aim of this study is the efficacy of autogenic and allogenic natural killer (nk) immunotherapy on recurrent solid tumors.

by enrolling patients with multiple kinds of solid tumor adapted to enrolled criteria, this study will document for the first time the short/long term efficacy of auto/allogenic nk cells.the outcome will be evaluated according to local relief degree, progress free survival (pfs) and overall survival (os).

Eligibility criteria:
inclusion criteria: * all standard therapies have failed according to nccn guidelines or the patient refuses standard therapies after cancer recurrence * body tumor 1-6, the maximum tumor length \< 5 cm * kps ≥ 70, lifespan \> 6 months * platelet count ≥ 80×109/l，white blood cell count ≥ 3×109/l, neutrophil count ≥ 2×109/l, hemoglobin ≥ 80 g/l exclusion criteria: * patients with cardiac pacemaker * patients with brain metastasis * patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction

Keywords: solid tumor nk immunotherapy
omalizumab in patients with moderate to severe persistent allergic asthma not adequately controlled despite gina (2009) step 4 therapy

Conditions: Persistent Allergic Asthma

Summary: this study will assess the efficacy, safety and tolerability of omalizumab, compared to placebo in 18 to 75 year old chinese patients with moderate to severe persistent allergic asthma who have inadequate asthma control despite treatment according to gina (2009) step 4 therapy.


Eligibility criteria:
inclusion criteria: * met study drug-dosing table eligibility criteria (serum baseline total ige level ≥ 30 to ≤ 700 iu/ml and body weight \> 20 kg and ≤ 150 kg) * diagnosed with asthma ≥ 1 year duration at screening, and a history of asthma that is not adequately controlled with gina (2009) step 4 therapy * received medium-to-high dose inhaled corticosteroid \> 500 µg beclomethasone diproprionate (bdp), or equivalent plus regularly inhaled laba, either separately or in combination, for at least 8 weeks prior to screening * met specific asthma exacerbations eligibility criteria prior to the screening period * exhibited inadequate symptom control as demonstrated by specific criteria (in keeping with gina 2009 guidelines) * positive skin prick test to at least one perennial aeroallergen documented by a historical test within 12 months prior to screening, or at visit 1 * fev1 ≥ 40% and \< 80% of the predicted normal value for the patient (using local standards), after withholding bronchodilators at visit 2 exclusion criteria: * used other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer. for biological agent-based investigational drugs, such as monoclonal antibodies, at least six months will need to have passed between the last administration of the drug and the patient's screening visit. * history of malignancy * history of allergies and diseases that could interfere with the analyses * clinically significant abnormality on a 12-lead ecg recorded at visit 1 * elevated ige levels for reasons other than allergy * current smokers, or a former smoker with a smoking history of \> 10 pack-years. a former smoker must have abstained for a minimum of 12 months before randomization * receiving specific medications * clinically significant laboratory abnormalities (not associated with the study indication) at visit 1 other protocol-defined inclusion/exclusion criteria may apply

Keywords: omalizumab asthma immunoglobulin e ige
immune monitoring of hepatitis c under daa therapy

Conditions: Hepatitis C

Summary: direct acting antivirals offer a new opportunity to monitor the immune response in hepatitis c infection. in this study cytokine markers will be measured during therapy up to time point svr 12 an correlated to clinical parameters and regular laboratory findings.


Eligibility criteria:
inclusion criteria: * written consent, age, hcv-rna positive, daa therapy exclusion criteria: -
metformin/rosuvastatin combination therapy with in patients with type 2 diabetes and dyslipidemia

Conditions: Type 2 Diabetes; Dyslipidemia

Summary: compare the efficacy and safety of metformin/rosuvastatin combination therapy with metformin or rosuvastatin monotherapy in patients with type 2 diabetes and dyslipidemia

multi-center, randomized, double-blind, phase iii clinical trial

Eligibility criteria:
inclusion criteria: * over 19 years * type ii dm with dyslipidemia * 6.5% ≤ hba1c \< 11% * triglyceride \< 350mg/dl * 100mg/dl ≤ ldl-c ≤ 250mg/dl * fpg ≤ 270mg/dl exclusion criteria: * type i dm * unstable angina, mi, stroke, cabg with 6 month from screening * sbp ≥ 180mmhg, dbp ≥ 110mmhg * tsh \> unl * heart failure (nyha class iii/iv) * serum creatinine \> unl or clcr \< 60 ml/min * ck ≥ 2x unl * hiv positive * bmi \> 40 kg/m\^2

Keywords: metformin rosuvastatin type 2 diabetes dyslipidemia
hepatitis c (hcv) cure and kidney health

Conditions: Hepatitis C

Summary: the purpose of this study is to learn how 12 weeks of hcv treatment with elbasvir and grazoprevir (brand name zepatier) impacts your kidney function.

prospective data collection of 25 genotype 1 or 4 hcv-infected women from the san francisco women's interagency hiv study (wihs) site and 25 genotype 1 or 4 hcv-infected men from the san francisco va medical center who are initiated on zepatier for 12 weeks (total n=50). for women and men with hcv genotype 1a infection, only those without baseline ns5a resistance mutations will be included. blood/urine samples will be collected before initiation of treatment, 4 weeks after treatment initiation, 12 weeks after treatment initiation (end of treatment), 24 weeks after treatment initiation to determine sustained virological response (svr), and at 48 weeks after treatment initiation.

Eligibility criteria:
inclusion criteria: 1. active genotype 1 or 4 hcv infection (if with genotype 1a infection, only those without baseline ns5a resistance mutation will be included; genotype 4 hcv infection is uncommon in both study populations). subjects with hiv coinfection are included. we will not exclude patients who have severe chronic kidney disease, are on dialysis, or have undergone kidney transplant. exclusion criteria: 1. hcv genotype 2, 3, 5, or 6 infection 2. previous virologic failure to regimens containing an ns5a inhibitor 3. decompensated liver disease (child-pugh class b or c) 4. albumin below 3g/dl 5. platelet count below 75,000 6. any condition that the investigator considers a contraindication to study participation including limited life expectancy 7. pregnant or breastfeeding woman 8. hepatitis b virus (hbv) surface antigen positive (note: patients positive for the hbv core antibody will not be excluded, but will have hbv dna levels checked and will be monitored while on direct acting antivirals (daa) therapy and medically managed as considered appropriate) 9. documented ongoing nonadherence to prescribed medications or medical treatment, failure to complete hcv disease evaluation appointments and procedures or unable to commit to scheduled followup/monitoring for the duration of treatment 10. poor venous access not allowing screening laboratory collection 11. known hypersensitivity to elbasvir/grazoprevir 12. co-administration with drugs that are 1) strong cyp3a inducers (e.g., phenytoin, carbamazepine, rifampin); 2) oatp1b1/3 inhibitors (e.g., cyclosporine, darunavir, atazanavir, tipranavir, lopinavir or saquinavir) or 3) efavirenz

Keywords: genotype 1 genotype 4
virtual reality on pain and fear levels of children with primary immunodeficiency

Conditions: Primary Immunodeficiency Diseases (PID)

Summary: in this study, it is aimed to investigate the effect of virtual reality and tablet video viewing intervention on pain and fear levels and vital signs of children during peripheral venous catheter placement for intravenous immunoglobulin (ivig) administration.


Eligibility criteria:
inclusion criteria: * being between the ages of 4-11 * being followed up with the diagnosis of primary immunodeficiency for at least 6 months * to accept participation in the study voluntarily * no additional chronic disease other than primary immunodeficiency exclusion criteria: * organ failure is present * having a mental deficiency * having a disability to use vr glasses * children with fever (\|\>37.5 c0) * children with severe dehydration

Keywords: children virtual reality primary immunodeficiency nursing care administration, intravenous
high-density activation mapping of the slow pathwayto guide catheter ablation in patients with typical atrioventricular nodal reentrant tachycardia

Conditions: Supraventricular Tachycardia; Atrioventricular Nodal Re Entrant Tachycardia

Summary: atrioventricular nodal reentrant tachycardia (avnrt) is the most common supraventricular tachycardia inducible during an electrophysiological study. although ablative therapy proved to be the treatment of choice, little is known about the components of the tachycardia circuit. the aim of this study is to detect the presence and patterns of specific electrograms representing slow pathway (sp) potentials and to explore koch's triangle pattern activation during sinus rhythm and/or atrial extraestimulus with a high-density mapping catheter in an attempt to clarify a fast and safety catheter ablation strategy. we hypothesized that, in patients with dual atrioventricular nodal physiology, during sinus rhythm (sr), high-density mapping (hdm) catheters could identify the sp signals, making possible to delineate small areas of slow conduction associated to abnormal electrograms on koch's triangle. on a second step, radiofrequency (rf) applications safety guided by the hdm obtained with this method, should interrupt the circuit far from the his region. finally, sp signals should disappear after the rf procedure when performing a new 3d hdm. a control group of patients without avn dual physiology should show absence of fragmented/slow conduction zones.


Eligibility criteria:
inclusion criteria: * patients \> 18 yo with avnrt observed after electrophysiological study exclusion criteria: * patients \< 18 yo
covid-19 : pulmonary ultrasound in primary care

Conditions: Covid19; Pulmonary Infection; Ultrasound Therapy; Complications; Respiratory Infection

Summary: covid-19 infection are characterized by fever and signs of acute respiratory infection. a worsening of respiratory symptoms that can lead to respiratory failure. the decompensation can then be brutal and require rapid recourse to respiratory assistance. the contribution of clinical examination (auscultation and monitoring of oxygen saturation in particular) remains unsatisfactory in predicting an unfavorable course. the interest of pulmonary ultrasound is known in the management of pulmonary infections. however, estimating the severity of lung damage at an early stage could be of great help in monitoring and caring for patients. ultrasound could meet this need in general practice, the chest scanner is often unavailable in these situations. ultrasound signs are associated with severe forms. the contribution of pulmonary ultrasound seems particularly interesting in the context of the reassessment of patients during the worsening phase of symptoms (d5-d10). estimate the prevalence of ultrasound signs in patients with an acute respiratory infection suspected or confirmed to be covid-19, at the time of the worsening phase (between d5 and d10 of the onset of symptoms). the prevalence of ultrasound lung lesions under covid-19 may be essential to consider the development of the ultrasound tool in primary care. indeed, if the contribution of ultrasound is now recognized in intensive care or emergency, its place in general medicine still raises questions.


Eligibility criteria:
inclusion criteria: 1. patients over 18 years of age with : * a clinical symptomatology suggesting an acute respiratory infection linked to covid-19 defined by the following two categories of symptoms: * sudden fever (or a feeling of fever) * respiratory signs (cough, dyspnea, chest tightness) or * an acute respiratory infection confirmed to covid-19 by the result of rt-pcr screening tests. 2. and presenting, at the time of inclusion between the 5th and 10th day of infection, one of the respiratory signs of severity felt: * dyspnea, shortness of breath or difficulty in breathing * chest pain or tightness exclusion criteria: 1. the presence of a severe form during the initial consultation. a severe form is defined by the presence of the following signs: * polypnea\> 22 / min * systolic bp \<90 mmhg * sp02 \<90% * altered consciousness, confusion, drowsiness * dehydration * alteration of the general condition in the elderly 2. the presence of acute respiratory signs clearly having a cause other than a covid-19 infection.

Keywords: covid19
a controlled clinical study of 2 different moisturizers for the relief of dry skin

Conditions: Skin; Skin Care; Skin Cream

Summary: dry skin is characterized by a lack of moisture in the outer layer of the skin and can occur as a result of numerous factors including cold weather, low humidity, age, etc. in this study, the moisturizing benefits of two formulas were evaluated for barrier function improvement/impact when used by women with moderately to severely dry skin on their lower legs.


Eligibility criteria:
inclusion criteria: * moderately to severely dry skin on both leg legs, as determined by the investigator. * fitzpatrick skin types i-iv * generally in good health * routinely uses moisturizers on the legs at least 1-3 times per week. * if of reproductive potential: using a medically acceptable form of birth control for at least 3 months before the study and willing to continue it for at least 1 month after study completion. * able to read, write, speak, and understand english. * willing and able to complete all study instructions. * has completed the informed consent document including a hipaa disclosure and photograph release. exclusion criteria: * known allergies/sensitivities to adhesive tapes or study product ingredients. * known skin conditions, uncontrolled medical conditions, or any other condition that could interfere with evaluations/data interpretation or increase risk to the subject. * any active bacterial/fungal/viral skin infections or susceptibility to such infections. * females who are pregnant, breastfeeding, or planning to become pregnant in near future. * compromised/broken skin, tattoos, scarring, excessive hair growth, very uneven skin tone, or other conditions that would interfere with evaluations or increase risk to the subject. * current participation in another study. * participation in another study in past 4 weeks. * employees or relatives of the investigator or study site.

Keywords: skin stratum corneum skin care skin cream dryness moisturization hydration
the pharmacokinetics of mk-7145 following single dose administration in participants with moderate renal insufficiency (mk-7145-018)

Conditions: Renal Insufficiency

Summary: the primary purpose of this study is to obtain a preliminary pharmacokinetic profile of mk-7145 2 mg immediate release (ir) following single-dose administration in male participants with moderate renal insufficiency. in addition, the study will evaluate the pharmacodynamic effect of a single dose of mk-7145 2 mg ir on 24-hour net natriuresis in male participants with moderate renal insufficiency.


Eligibility criteria:
inclusion criteria: * body mass index (bmi) 18 to 35 kg/m\^2 * nonsmoker and/or have not used nicotine or nicotine-containing products for at least 3 months prior to enrollment * estimated glomerular filtration rate (egfr) 30 to 60 ml/min/1.73 m\^2 exclusion criteria: * history of stroke, chronic seizures, or major neurological disorder * ongoing, clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, respiratory, or genitourinary abnormalities or diseases * systolic blood pressure (sbp) ≤95 mmhg or \>160 mmhg, or diastolic blood pressure (dbp) ≤45 mmhg or \>95 mmhg * history of neoplastic disease except for adequately treated non-melanomatous skin carcinoma * unable to refrain from, or anticipates the use of, strong/moderate cytochrome p450 3a4 (cyp3a4) inhibitors * consumes excessive amounts of alcohol, defined as greater than 3 glasses of alcoholic beverages, wine, or distilled spirits per day * consumes excessive amounts of caffeine, defined as greater than 6 servings of coffee, tea, cola, or other caffeinated beverages per day * had major surgery or donated blood within 8 weeks prior to enrollment * has participated in another investigational study within 4 weeks prior * history of significant multiple and/or severe allergies (including latex allergy), or has had an anaphylactic reaction or significant intolerance to prescription or nonprescription drugs or food * currently a regular user of illicit drugs, or has a history of drug (including alcohol) abuse within approximately 6 months * has active or has a history of nephrolithiasis * has had a kidney removed or has a functioning renal transplant